COMP <GO>
PCVX vs UNH // REVENUE GROWTH (YOY)
Vaxcyte Inc. (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: PCVX 3
— UNH 9
▲ REVENUE GROWTH (YOY) LEADER: PCVX
LAST: $60.62 (-2.27%) • MKT CAP: $9.54B
revenue-growth
19.80%
LAST: $400.44 (-1.60%) • MKT CAP: $359.43B
revenue-growth
3.33%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PCVX VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PCVX | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 88.31% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -27.60% | 12.38% | -39.98 | UNH | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 15.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -6.79% | 6.25% | -13.04 | UNH | /fcf-yield <GO> |
| Operating Margin | -33.50% | 5.32% | -38.82 | UNH | /operating-margins <GO> |
| Net Profit Margin | 0.00% | 3.53% | -3.53 | UNH | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | 19.80% | 3.33% | +16.47 | PCVX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.29% | -2.29 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 18.11 | 3.09 | +15.02 | PCVX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 7/9 | -3.00 | UNH | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 7.00% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 45.3 | 55.1 | -9.80 | UNH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.07 | 0.33 | +0.74 | PCVX | /macro-sensitivity <GO> |
| Forward P/E Multiple | 23.0x | 17.7x | +5.26 | UNH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $9.54B | $359.43B | -$349.89B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PCVX REV | UNH REV | PCVX GROSS % | UNH GROSS % | PCVX FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.59B | $447.57B | — | 88.7% | -$669.3M | $16.07B |
| FY 2024 | $1.59B | $400.28B | — | 88.3% | -$475.1M | $20.70B |
| FY 2023 | $1.31B | $371.62B | — | 89.6% | -$296.8M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PCVX // BETA 1.07
UNH // BETA 0.33